Learn more about our Legal work.
AdvaMed urged California’s First District Court of Appeal to overturn an erroneous decision by the trial court that has the potential to impose unfair and unwarranted liability upon companies that…
In recent years, private investors have been subject to increased government enforcement scrutiny under the False Claims Act. Given investors’ vital role in medtech, AdvaMed developed tools and resources to…
Pat Fogarty sat down with industry observer Jack Kalavritinos for a Q&A to discuss the current landscape of litigation in the medical device industry.
These arrangements to advance value-based care are designed to increase shared accountability among shareholders for quality of, access to and/or the total cost of care.
AdvaMed publishes a quarterly attorney ad spend tracker, which highlights the amount of money spent on medical device mass tort television advertising.
Sidley’s Global Life Sciences group looks at 12 forces driving the life sciences legal and regulatory landscape in 2022, and provides practical tips on a range of topics for life…
Non-lawyer firm ownership poses particular risks to the medical device industry and the patients & care givers medtech innovators serve every day.
As medtech innovation outpaces coding and payment systems designed for another era, the threat of meritless False Claims Act cases deters important advancement in technologies patients need.